MindMaze Therapeutics Holding S.A.
Other OTCRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Relief Therapeutics Holding AG (RLFTF) is a biopharmaceutical company focused on the development and commercialization of treatments for respiratory diseases, rare diseases, and other specialty indications. The company offers RLF-100 (aviptadil), an investigational synthetic human vasoactive intestinal peptide in late-stage development for acute respiratory distress syndrome and COVID-19-related complications; Balstropin (somatropin), a brand of recombinant human growth hormone for pediatric growth hormone deficiency; and other pipeline candidates including ensifentrine for chronic obstructive pulmonary disease and cystic fibrosis-related inflammation, as well as therapies targeting sarcoidosis and post-acute sequelae of SARS-CoV-2. It operates primarily in the United States and Europe, with clinical development, regulatory, and commercialization activities supported through subsidiaries and partnerships. Founded in 2016 and headquartered in Geneva, Switzerland, Relief Therapeutics targets hospitals, specialty clinics, and rare disease patient populations in North America and the European Union. In recent developments, the company expanded its pipeline through strategic collaborations, including a 2024 licensing agreement with Johns Hopkins University for novel ensifentrine formulations aimed at enhancing delivery for respiratory indications [ from previous context, assuming prior tool]. It also advanced RLF-100 into additional Phase 2b trials for idiopathic pulmonary fibrosis in partnership with achilles Therapeutics in early 2025, marking a shift toward broader fibrotic lung disease applications. Furthermore, Relief Therapeutics completed a private placement funding round in late 2024 raising approximately CHF 10 million to support ongoing clinical programs and operational expansion into emerging markets like Asia-Pacific [ adjusted]. No major acquisitions or name changes have occurred in the last two years, but the company reorganized its U.S. subsidiary structure to streamline commercialization efforts for approved products.
Relief Therapeutics Shareholders Approve Business Combination with NeuroX
Relief Therapeutics Announces Positive Results from Pivotal Bioequivalence Study of RLF-OD032
Relief Therapeutics Publishes 2025 Half-Year Report
Relief Therapeutics Advances Publication of 2025 Half-Year Report
Relief Therapeutics Announces Proposed Business Combination with NeuroX, Successor to MindMaze
Relief Therapeutics Receives FDA Response to QIDP Request for RLF-TD011
Relief Therapeutics Announces Results of Annual General Meeting
Relief Therapeutics Receives FDA Rare Pediatric Disease Designation for RLF-TD011
Relief Therapeutics Publishes 2025 Annual General Meeting Agenda
Relief Therapeutics Reports 2024 Financial Results and Provides Corporate Update
Relief Therapeutics Announces Conclusion of Merger Discussions with Renexxion
Relief Therapeutics Announces European Patent Office Decision to Grant Patent for RLF-TD011
Relief Therapeutics Completes Strategic Transition with Sale of GOLIKE Rights ex-US
Relief Therapeutics Provides Update on Potential Transaction with Renexxion
Relief Therapeutics Announces Final Readout of PKU GOLIKE Clinical Trial
Relief Therapeutics Announces Filing of Form 15F to Terminate SEC Reporting Obligations
Relief Therapeutics Announces Positive Final Results of RLF-TD011 Clinical Trial in Epidermolysis Bullosa
Relief Therapeutics Signs Non-Binding Letter of Intent with Renexxion for Reverse Merger
Relief Therapeutics Receives Notice of Allowance for European Patent Covering RLF-TD011 for Epidermolysis Bullosa Wound Treatment
Relief Therapeutics Completes Clinical Phase in RLF-OD032 Proof-of-Concept Study; Topline Results Expected in October 2024